同源康医药－Ｂ 02410 Stock Information

// Company Overview //

Stock Name	同源康医药－Ｂ
Stock Code	02410
Company Full Name	同源康医药－Ｂ
Industry	醫療保健
Principal Activities	公司是一家臨床階段的生物制藥公司，致力于發現、收購、開發差異化靶向治療并對其進行商業化，以滿足癌癥治療中亟待滿足的醫療需求。
Listing Date	2024-08-20
Listing Rules Era	Old Rules
Listing Rules Chapter	No data
Weighted Voting Rights (WVR)	No
Registered Address (Mainland China)	中國浙江省湖州市長興經濟開發區明珠路1278號長興世貿大廈A座14層1403-2室
Business Address (Hong Kong)	No data
Place of Incorporation	No data
Listing Method	No data
Listing Board	Main Board
Website	http://www.tykmedicines.com/
Share Registrar	卓佳证券登记有限公司 (Tricor Investor Services Limited)
Registrar Contact	(852)2862 8628
A-Share/US Dual Listing	No data

// Offering Information //

Offering Mechanism	未知
Clawback Tiers	No data
Prospectus Date	2024-08-12
Offer Price	HK$ 12.10 / shares
Offer Price Range	Final offer price only, no range
Lot Size	500 shares
Entry Threshold	HK$ 6,050
Par Value	No data
Global Offering Shares	47,880,000
HK Public Offering Shares	— (0.0%)
International Placing Shares	— (0.0%)
Offer Ratio	No data
Total Shares Post-IPO	No data
Total Global Offering Size	HK$ 579,348,000
Public Offering Size	HK$ — (0.0%)
Oversubscription Multiple	2.3x
Valid Applications	974
Accepted Applications	649
Reallocation	No
Total Funds Raised	HK$ 57,934,800
Greenshoe (Over-allotment Option)	No data

// Valuation & Financials //

Market Cap (at Offer Price)	HK$ 0
Pre-IPO Valuation (Last Round)	No data
P/E Ratio	-10.70
Profit/Loss Status	No data
Period-End Cash Balance	No data
Listing Expenses	~HK$ 73,040,000
Listing Expenses / Funds Raised	No data
Total Pre-IPO Investment	No data

// First Day Performance

// Price Chart //

// Use of Proceeds

Use of Proceeds	1、70.0%或約354.4百萬港元將用于核心產品（即TY-9591）的研究、開發及商業化； 2、20.0%或約101.3百萬港元將用于其他候選產品的研發； 3、3.0%或約15.2百萬港元將用于潛在的戰略收購、投資、許可或合作機會； 4、7.0%或約35.4百萬港元將用于營運資金及其他一般公司用途。

// Underwriting Syndicate //

独家保荐人 (1)

中信证券（香港）有限公司

整体协调人 (4)

中信里昂证券有限公司德意志银行香港分行招银国际融资有限公司海通国际证券有限公司

联席账簿管理人 (6)

中信里昂证券有限公司德意志银行香港分行招银国际融资有限公司海通国际证券有限公司中银国际亚洲有限公司利弗莫尔证券有限公司

联席牵头经办人 (6)

中信里昂证券有限公司德意志银行香港分行招银国际融资有限公司海通国际证券有限公司中银国际亚洲有限公司利弗莫尔证券有限公司

// Cornerstone Investors // Allotment Results Announcement

#	Investor Name	Shares Subscribed	% of Offer Shares	% of Total Shares	Lock-up Period	Est. Unlock Date
1	鄭州泰	100,000,000	—	—	2025-08-19	2025-08-19

// Directors & Management //

Chairman	吳豫生
Company Secretary	黃詠儀

No director data available.

// Major Shareholders //

Major Shareholders & Holdings	鄭州泰基鴻諾醫藥股份有限公司(26.97%),長興利源企業管理合伙企業(有限合伙)(6.11%)

// Allotment Benchmarks //

Pool A (Small Subscriptions)

Shares Applied	Applicants	Allottees	Expected Lots
500	614	294	0.48
1,000	117	112	0.96
1,500	37	16	1.43
2,000	36	32	1.89
2,500	18	6	2.33
3,000	19	15	2.79
3,500	8	2	3.25
4,000	20	14	3.70
4,500	1	1	4.00
5,000	23	10	4.43
6,000	5	1	5.20
7,000	2	2	6.00
8,000	7	5	6.71
9,000	7	2	7.29
10,000	18	18	8.00
15,000	3	3	12.00
20,000	5	5	16.00
25,000	3	3	20.00
30,000	3	3	24.00
50,000	3	3	40.00
60,000	1	1	48.00
70,000	1	1	56.00
80,000	1	1	63.01
90,000	1	1	70.00
100,000	5	5	77.00
200,000	4	3	153.76
300,000	5	3	230.58
400,000	3	1	307.36

Pool B (Large Subscriptions)

Shares Applied	Applicants	Allottees	Expected Lots
500,000	1	1	480.00
1,250,000	1	1	1197.00
1,500,000	1	1	1436.10
1,750,000	1	1	1675.10

Allotment Benchmarks

同源康医药－Ｂ 02410Stock Information